Search results
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 4 days agoResults for the ACE-Breast-02 study were presented at the American Society of Clinical Oncology 2024...
Seagen's breast cancer therapy succeeds in late-stage study
Reuters via Yahoo News· 10 months agoPfizer in March agreed to acquire Seagen and its targeted therapies in a $43 billion deal to help...
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
Zacks via Yahoo Finance· 10 months agoSeagen Inc. SGEN announced positive top-line results from its late-stage HER2CLIMB-02 study,...
'I'm a people lover': Cancer patient volunteers for clinical trials to help others
Savannah Morning News via Yahoo News· 7 months agoCancer care is constantly improving at Lewis Cancer Research Pavilion and clinical trial...
Roche sceptical about investing more in 'guided-missile' ADC cancer drugs
Reuters via Yahoo News· 2 years agoMANNHEIM (Reuters) -Roche remains sceptical about investing more in antibody-drug conjugates (ADCs),...
AbbVie joins ADC dealmaking with $10B ImmunoGen buyout
BioPharma Dive via Yahoo Finance· 6 months agoAbbVie is expanding its investment in targeted cancer medicines, announcing Thursday a $10.1 billion...
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Zacks via Yahoo Finance· 6 months agoRoche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone...
AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer
Zacks via Yahoo Finance· 2 years agoThe EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to...
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Zacks via Yahoo Finance· 3 weeks agoRoche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced...
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
Zacks via Yahoo Finance· 2 years agoSwiss pharma giant Roche Holding AG’s RHHBY third-quarter revenues declined 6% to CHF 14.7 billion...